Abstract:OBJECTIVE Resection, chemotherapy, radiation therapy, and tumor treating fields significantly increase the overall survival (OS) of glioblastoma (GBM) patients. Yet, cost and healthcare disparities might limit access. Multiple studies have attributed more than 80% of the GBM disease burden to White patients. The aim of this study was to explore the intersections of race and social determinants of health (SDoH) with healthcare access and outcomes of GBM patients in a large metropolitan area. METHODS In this retrospective single-center study, the tumor registry at the authors’ institution (2011–2019) was queried to identify a GBM cohort according to the updated WHO criteria. Data were supplemented by electronic health records to include demographics, outcome, National Cancer Institute Comorbidity Index (NCI-CI), and the Agency for Healthcare Research and Quality (AHRQ) socioeconomic status (SES) index. RESULTS A total of 276 unique patients met the study inclusion criteria; 46% of the cohort was female, and 45% was non-White. This racial proportion differs from previous reports indicating that 80% of patients with GBM are White. The proportion of non-White patients in this study was similar to that of the general US population and significantly lower than that of New York City (p < 0.05). Non-White patients predominantly composed the lowest AHRQ SES index quartile, while White patients constituted the highest quartile (p < 0.001). White patients were older at diagnosis compared with non-White patients (63 vs 58 years, p = 0.001). Older age (p = 0.03), higher NCI-CI (p = 0.0006), and lack of insurance (p = 0.03) reduced the odds of a home discharge. Private insurance (p = 0.005), younger age (p = 0.02), and the highest ("wealthiest") AHRQ SES index quartile (p = 0.02) predicted a lower hospital length of stay (LOS). Patients who underwent gross-total resection had greater OS than those who received a subtotal resection or biopsy, independent of race and SDoH (1.68 vs 1.4 years, p = 0.022). CONCLUSIONS This study is the first to report on race and SDoH of a cohort using the latest WHO criteria for GBM classification. In contrast to previous literature, the study cohort exhibits a higher proportion of non-White patients with GBM, similar to the representation of non-White individuals in the general US population. This study corroborates the impact of SDoH and not race on LOS and discharge location. Initiatives to identify and address these barriers are crucial for enhancing the care of all GBM patients.

Treatment, healthcare utilization and outcomes in patients with glioblastoma in Ontario: a 10-year cohort study

Epid-18. Patterns Of Care And Clinical Outcomes Of Patients With Glioblastoma From 2005-2020: A Real-World Analysis

Radt-38. Clinical, Molecular And Imaging Features Associated With Long Term Survival In Glioblastoma Patients

Long-Term Time Series Forecasting and Updates on Survival Analysis of Glioblastoma Multiforme: A 1975-2018 Population-Based Study

Ten-year survival in glioblastoma. A systematic review

The intersection of race and social determinants of health on clinical outcome of glioblastoma patients

EPID-34. GEODEMOGRAPHIC CLASSIFICATION OF GLIOBLASTOMA RISK IN A RURAL HOSPITAL SYSTEM: RELATIONSHIP TO TUMOR INCIDENCE AND OVERALL SURVIVAL

Disp-02. Socioeconomic Factors Influence Overall Survival In Chemoradiation-Treated Newly Diagnosed Who Grade 4 Glioblastoma

Qol-11. Gbm Patients Continue To Face Barriers To Personalized And Comprehensive Care That May Impact Longevity And Quality-Of-Life

Biophysical and Biological Mechanisms of Tumor Treating Fields in Glioblastoma

Biom-63. Long-Term Survival And Molecular Characterization Of Idh-Wildtype Glioblastoma In An Asian Cohort

Clinical features associated with the efficacy of chemotherapy in patients with glioblastoma (GBM): a surveillance, epidemiology, and end results (SEER) analysis

Approaches in Adult Glioblastoma Treatment: A Systematic Review of Emerging Therapies

An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment

Prognosis of glioblastoma patients improves significantly over time interrogating historical controls

Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance

Differences in clinical outcomes based on molecular markers in glioblastoma patients treated with concurrent tumor-treating fields and chemoradiation: exploratory analysis of the SPARE trial

Review of Novel Surgical, Radiation, and Systemic Therapies and Clinical Trials in Glioblastoma

Molecular Characterization and Survival Analysis of a Cohort of Glioblastoma, IDH-wildtype

Glioblastoma Multiforme: The Latest Diagnostics and Treatment Techniques

Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project